Press release
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
– Long-Term & Real-World HIV Research Offer Insights into How Treatment with Biktarvy® and Sunlenca® May Help Inform the Future of Coordinated,
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n– Long-Term & Real-World HIV Research Offer Insights into How Treatment with Biktarvy® and Sunlenca® May Help Inform the Future of Coordinated, Person-Centered HIV Care –\n\n\n– Updates on Collaborations with the Global HIV Community Include Initiatives Aimed at Advancing Efforts to End the Epidemic in Eastern Europe and Central Asia –\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 19th European AIDS Conference (EACS) to be held in Warsaw, Poland from October 18-21, 2023. As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs. The research that will be presented at EACS 2023, along with symposia led by Gilead, reflects the company’s person-centered approach to advancing scientific innovation and underscores its focus on community partnership to help end the HIV epidemic.\n\n\n“At Gilead, our person-centered approach to science involves engaging community voices in the research process from the initial planning stages of new compounds to the real-world and patient-reported outcomes of approved medicines,” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. “Our commitment to transformative innovation goes beyond the laboratory. Innovative approaches to collaborating at the global, national, and local levels have the potential to address the diverse needs of people and communities affected by HIV and improve linkage to and retention in care.”\n\n\nScientific Progress in HIV Research\n\n\nAt EACS 2023, Gilead will present new findings on long-acting HIV treatment strategies, including outcomes from multiple studies evaluating twice-yearly lenacapavir, Gilead’s first-in-class, long-acting HIV-1 capsid inhibitor. These findings will include insights, experience and perspectives from healthcare professionals and study coordinators from CAPELLA, an ongoing Phase 2/3 registrational study designed to evaluate the antiviral activity and safety of twice-yearly lenacapavir administered as a subcutaneous injection in adults with multi-drug resistant HIV who are heavily treatment experienced. Additional lenacapavir data presented at EACS 2023 will provide insight into the therapy’s resistance...